In the European Union,<unk>  is indicated for the treatment of mild-to-moderate idiopathic pulmonary fibrosis. It was approved by the European Medicines Agency in 2011. In October 2008, it was approved for use in Japan, in India in 2010, and in China in 2011 (commercial launch in 2014). In October 2014, it was approved for medical use in the United States. A tablet version was approved for use in the United States in January 2017. In Mexico it has been approved on a gel form for the treatment of scars and fibrotic tissue and has proven to be effective in the treatment of skin ulcers
Pirfenidone
Lurasidone
Chlortalidone
Methylphenidate
Dexmethylphenidate
Rimonabant
Ethylphenidate
Pirlindole